Document detail
ID
oai:HAL:hal-02997588v1
Topic
peripheral neuropathy oxaliplatin colorectal cancer health-related quality of life cancer survivors [SDV.NEU]Life Sciences [q-bio]/Neu...Author
Selvy, Marie Pereira, Bruno Kerckhove, Nicolas Gonneau, Coralie Feydel, Gabrielle Pétorin, Caroline Vimal-Baguet, Agnès Melnikov, Sergey Kullab, Sharif Hebbar, Mohamed Bouché, Olivier Slimano, Florian Bourgeois, Vincent Lebrun-Ly, Valérie Thuillier, Frédéric Mazard, Thibault Tavan, David Benmammar, Kheir Eddine Monange, Brigitte Ramdani, Mohamed Péré-Vergé, Denis Huet-Penz, Floriane Bedjaoui, Ahmed Genty, Florent Leyronnas, Cécile Busserolles, Jérôme Trevis, Sophie Pinon, Vincent Pezet, Denis Balayssac, DavidLangue
enEditor
HAL CCSD;MDPI
Category
sciences: life sciences
Year
2020
listing date
12/15/2023
Keywords
quality neuropathy life colorectal study oxaliplatin peripheral patients prevalence cipn cancerAbstract
International audience; (1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs.
Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer.
(2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy.
(3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8-36.0).
Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain.
CIPN was associated with anxiety, depression, and deterioration of quality of life.
None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively.
(4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN.
The present study showed marked psychological distress and uncovered a failure in management in these patients.
Selvy, Marie,Pereira, Bruno,Kerckhove, Nicolas,Gonneau, Coralie,Feydel, Gabrielle,Pétorin, Caroline,Vimal-Baguet, Agnès,Melnikov, Sergey,Kullab, Sharif,Hebbar, Mohamed,Bouché, Olivier,Slimano, Florian,Bourgeois, Vincent,Lebrun-Ly, Valérie,Thuillier, Frédéric,Mazard, Thibault,Tavan, David,Benmammar, Kheir Eddine,Monange, Brigitte,Ramdani, Mohamed,Péré-Vergé, Denis,Huet-Penz, Floriane,Bedjaoui, Ahmed,Genty, Florent,Leyronnas, Cécile,Busserolles, Jérôme,Trevis, Sophie,Pinon, Vincent,Pezet, Denis,Balayssac, David, 2020, Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study, HAL CCSD;MDPI
Evaluating Image Hallucination in Text-to-Image Generation with Question-Answering
evaluation computer dataset images tti generation i-halla
Role of Repetitive Transcranial Magnetic Stimulation in Treatment of Fibromyalgia: A Randomized Controlled Trial
significant following stimulation fms treatment
